Alex Philippidis

Martin A. Makary, MD, a surgeon and public policy researcher at Johns Hopkins University who has taken public positions at odds with public health

Credit: da-kuk/Getty Images Benevolent AI Benevolent is counting on co-founder Ken Mulvany to turn the company around from two years

Novartis will partner with PTC Therapeutics to expand the use of PTC's small molecule splicing platform to develop PTC's PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license and collaboration agreement, the companies said today.

Enveda's pipeline is led by ENV-294, a first-in-class, oral small molecule being developed to treat atopic dermatitis and other inflammatory conditions by combining the advantages of blockbuster drugs now marketed for the skin disorder.

Amgen said today it will raise its biomanufacturing investment in Holly Springs, NC, to $1.5 billion, by establishing a second drug substance manufacturing plant there—thanks in part to nearly $5 million in economic subsidies from North Carolina.

Cathie Wood says a "cure" can generate up to 20x more value than traditional drugs, which appears to explain why two of her firm's funds snapped up shares of the Casgevy co-developer until this past week.

ISM5411 is designed to directly regulate the intestinal immune microenvironment so that the drug simultaneously reduces the gut inflammation seen in IBD while also promoting the repair of the intestinal mucosal barrier.

Q32 Bio faced a sharp market reaction as shares plunged 85% following mixed mid-stage trial results for its lead candidate, bempikibart, in alopecia areata and atopic dermatitis. The stock closed just $0.03 above its 52-week low.

NVentures invests further in Stanford spinout to accelerate development of platform designed to optimize molecules for complex targets in oncology, immunology

GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five performing biotech stocks of 2024, and the five biotech stocks that fell the most during this past year, with brief explanations for the increases or declines.